Drug profile · INN
erythromycin estolate
ERYTHROMYCIN ESTOLATE
erythromycin estolate (ERYTHROMYCIN ESTOLATE) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — erythromycin estolate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
erythromycin estolate (ERYTHROMYCIN ESTOLATE) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is erythromycin estolate?
erythromycin estolate (ERYTHROMYCIN ESTOLATE) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for erythromycin estolate?
ERYTHROMYCIN ESTOLATE is a marketed brand name for erythromycin estolate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of erythromycin estolate?
erythromycin estolate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.